Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 91 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell CarcinomaCompletedNCT01513187Phase 1/2
• Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedNCT01511289Phase 3
• First Line Gefitinib by FDG-PET Metabolic ResponseStatus unknownNCT01510990Phase 2
• Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular CarcinomaCompletedNCT01507064Phase 2
• A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT01506934Phase 1
• Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibCompletedNCT01506336Phase 2
• Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic CancerCompletedNCT01505413Phase 2
• Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male VolunteersCompletedNCT01504984Phase 1
• A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaStatus unknownNCT01503502Phase 2
• FLO +/- Pazopanib as First-line Treatment in Advanced Gastric CancerCompletedNCT01503372Phase 2
• Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never SmokersStatus unknownNCT01502202Phase 2
• A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung CancerWithdrawnNCT01500824Phase 2
• Study of Efficacy and Safety of Sunitinib Given on an Individualized ScheduleCompletedNCT01499121Phase 2
• A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy VolunteersCompletedNCT01499004Phase 1
• Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue SarcomaCompletedNCT01498835Phase 1
• Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung CancerCompletedNCT01498562Phase 2
• Dose-Escalation and Safety Trial of YN968D1CompletedNCT01497704Phase 1/2
• Lapatinib and Bortezomib in Patients With Advanced MalignanciesTerminatedNCT01497626Phase 1
• Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT01497444Phase 1
• Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary CancersCompletedNCT01497392Phase 1
• The Myocet/Lapatinib Study. ICORG 10-03, V5TerminatedNCT01495884Phase 1/2
• Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult SubjectsCompletedNCT01493869Phase 1
• Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
• KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedNCT01487174Phase 3
• A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic RetinopathyCompletedNCT01487070Phase 1
• Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)Status unknownNCT01486771Phase 4
• Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal CancerCompletedNCT01486251Not applicable
• A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KCompletedNCT01486017Phase 1
• A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.CompletedNCT01485926Phase 2
• Doxorubicin + BIBF 1120 in Patients for Ovarian CancerTerminatedNCT01485874Phase 1
• Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line ChemotherapyCompletedNCT01485809Phase 2
• Dose Escalation Study of Pazopanib Plus TH-302CompletedNCT01485042Phase 1
• A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New FormulationCompletedNCT01484964Phase 1
• A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01484847Not applicable
• Axitinib as Maintenance Treatment in Patients With Metastatic CRCTerminatedNCT01483638Phase 2
• Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01483014Phase 2
• Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial CancerCompletedNCT01482728Early Phase 1
• SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular CarcinomaCompletedNCT01482442Phase 3
• A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell OriginCompletedNCT01482377Phase 1
• A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT01480141Phase 2
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
• Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast CancerTerminatedNCT01477060Phase 2
• Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerTerminatedNCT01471964Phase 1/2
• Phase I Dose Escalating Study of TKI258CompletedNCT01471548Phase 1
• Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR MutationsStatus unknownNCT01470716Phase 2
• A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaTerminatedNCT01470131Phase 3
• A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01468467Phase 1
• AZD7451 for Recurrent GliomasCompletedNCT01468324Phase 1
• Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk NeuroblastomaCompletedNCT01467986Phase 2
• A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)CompletedNCT01466647Phase 1
• Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)WithdrawnNCT01465815Phase 1/2
• Dose Escalation Of Icotinib In Previously Treated Patients With Routine DoseCompletedNCT01465243Phase 4
• Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal CarcinomaCompletedNCT01462474Phase 1
• Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaCompletedNCT01460693Phase 3
• Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedNCT01456676Phase 1
• Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid TumorsCompletedNCT01455584Phase 1
• Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid TumorsCompletedNCT01455571Phase 1
• TUSC2-nanoparticles and Erlotinib in Stage IV Lung CancerTerminatedNCT01455389Phase 1/2
• Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsCompletedNCT01454804Phase 1
• A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or CarcinosarcomaStatus unknownNCT01454479Phase 1
• Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisCompletedNCT01450488Phase 2
• Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid TumorsCompletedNCT01450384Phase 1
• PF-00299804 in Patients With Head and Neck Squamous Cell CarcinomaCompletedNCT01449201Phase 2
• Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral CorticosteroidsCompletedNCT01449162Phase 3
• Dasatinib in Combination With Bevacizumab to Treat Advanced Solid TumorsCompletedNCT01445509Phase 1
• Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the MetastasesStatus unknownNCT01444807Phase 2
• Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic FunctionCompletedNCT01443481Phase 1
• Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed UterineCompletedNCT01442662Phase 2
• A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
• BIBF 1120 as Second Line Treatment for Small Cell Lung CancerCompletedNCT01441297Phase 2
• -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerTerminatedNCT01441128Phase 1
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
• Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and CholangiocarcinomaCompletedNCT01438554Phase 1
• Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyCompletedNCT01434303Phase 1
• Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisCompletedNCT01433497Phase 3
• Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
• Phase 1 Trial With SIR-Spheres and Cetuximab +/- ErlotinibWithdrawnNCT01432119Phase 1
• Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss PatientsCompletedNCT01430572Phase 1
• A Study to Assess the Bioavailability of ASP015KCompletedNCT01430078Phase 1
• Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy VolunteersCompletedNCT01430065Phase 1
• A Phase I Study of E7050 in Subjects With Solid TumorsCompletedNCT01428141Phase 1
• Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and NeckCompletedNCT01427478Phase 3
• Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic DiseaseTerminatedNCT01427322Early Phase 1
• Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT01427205Phase 2
• Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib MesylateTerminatedNCT01426334Phase 1
• Sorafenib for Patients With Extensive KeloidsTerminatedNCT01425216Phase 2
• Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT01424982Phase 2
• Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast CancerCompletedNCT01423123Phase 1
• Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
• Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid TumorsCompletedNCT01421004Phase 1
• Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2
• Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy SubjectsCompletedNCT01419990Phase 1
• A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal FunctionCompletedNCT01419041Phase 1
• Dovitinib in Adenoid Cystic CarcinomaCompletedNCT01417143Phase 2
• A Phase I Study of Henatinib in Patients With Advanced Solid MalignanciesTerminatedNCT01416623Phase 1
• Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC PatientsCompletedNCT01415674Phase 2
• Efficacy and Safety Study of Afatinib to Treat Lung Cancer PatientsCompletedNCT01415011Phase 2
• An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT01413893Phase 1
• Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By SurgeryCompletedNCT01413113Phase 1

← Tyrosine Kinase Inhibitors overview